Trials / Completed
CompletedNCT02781311
A Safety and Efficacy Study of Setipiprant Tablets in Androgenetic Alopecia in Males
Multicenter, Randomized, Double-Blind, Placebo-Controlled, Phase 2A Study of Setipiprant Tablets in Androgenetic Alopecia in Males
- Status
- Completed
- Phase
- Phase 2
- Study type
- Interventional
- Enrollment
- 169 (actual)
- Sponsor
- Allergan · Industry
- Sex
- Male
- Age
- 18 Years – 49 Years
- Healthy volunteers
- Not accepted
Summary
This study will evaluate the safety, tolerability and efficacy of the oral administration of setipiprant tablets 1000 mg twice daily (BID) relative to placebo in 18 to 49 years old males with androgenetic alopecia (AGA).
Conditions
Interventions
| Type | Name | Description |
|---|---|---|
| DRUG | Setipiprant | Setipiprant tablets, orally, BID for 24 weeks. |
| DRUG | Placebo | Placebo tablets, orally, BID for 24 weeks. |
| DRUG | Finasteride | Finasteride tablet, orally, once daily for 24 weeks. |
Timeline
- Start date
- 2016-07-14
- Primary completion
- 2018-03-15
- Completion
- 2018-05-22
- First posted
- 2016-05-24
- Last updated
- 2019-04-05
- Results posted
- 2019-04-05
Locations
18 sites across 1 country: United States
Regulatory
- FDA-regulated drug study
Source: ClinicalTrials.gov record NCT02781311. Inclusion in this directory is not an endorsement.